MedTrace Logo

Interleukin-2 in Metastatic Kidney Cancer

NCT01702909 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.

Conditions

  • Renal Cell Cancer Metastatic
  • Kidney Cancer Metastatic

Interventions

DRUG

Interleukin-2

Interleukin-2

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Walter Quan, MD · Western Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702909 on ClinicalTrials.gov